Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer

Fadi S Farhat 1Arafat TfayliNajla FakhruddinRami MahfouzZaher K OtrockRaafat S AlameddineAhmad H AwadaAli Shamseddine


1Hammoud Hospital University Medical Center, Saida, Lebanon.

PMID: 22494932

DOI: 10.1016/j.critrevonc.2012.02.012


Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still poor and the median survival for patients presenting with advanced non-small cell lung cancer (NSCLC) is only 8-10 months. Angiogenesis is an important biological process and a relatively early event during lung cancer pathogenesis. Anti-angiogenic agents are used in treating patients with NSCLC, and their molecular biomarkers are also being assessed to predict response. A better understanding of the biology of angiogenesis in NSCLC may reveal new targets for treating this malignancy. In this article, we review the expression and prognostic impact of the angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor, in NSCLC.